Safety and Efficacy of the Neuroform Atlas Stent for Treatment of Intracranial Aneurysms
Autor: | Sara Sciacca, Shahram Derakhshani, Lakshmi Kanagarajah, Juveria Siddiqui, Jeremy Lynch |
---|---|
Rok vydání: | 2020 |
Předmět: |
Male
medicine.medical_specialty medicine.medical_treatment 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Aneurysm Occlusion medicine Humans Radiology Nuclear Medicine and imaging Neuroradiology business.industry Mortality rate Stent Intracranial Aneurysm Middle Aged medicine.disease Neurovascular bundle Embolization Therapeutic Blood Vessel Prosthesis Cerebral Angiography Treatment Outcome Meta-analysis Stents Neurology (clinical) Neurosurgery Radiology business 030217 neurology & neurosurgery |
Zdroj: | Clinical Neuroradiology. 31:1167-1180 |
ISSN: | 1869-1447 1869-1439 |
DOI: | 10.1007/s00062-020-00979-y |
Popis: | The Neuroform Atlas (Stryker Neurovascular, Fremont, CA, USA) is a low-profile laser cut self-expanding nitinol stent designed to provide coil support and wall apposition during aneurysm embolisation. In this study, we performed a meta-analysis of outcomes after treatment with the Neuroform Atlas stent for the purpose of coil embolisation. The primary objectives of this meta-analysis were to define the safety (treatment-related complications, neurologic outcomes, mortality rate) and the efficacy (aneurysm occlusion rate) of the treatment of intracranial aneurysms with the Neuroform Atlas stent. A systematic review and meta-analysis was performed by searching PubMed, EMBASE, and the Cochrane CENTRAL Library for all published studies on the treatment of intracranial aneurysms with the Neuroform Atlas device up to 6 April 2020. The review was prepared in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A total of 14 studies were analysed (577 patients with 593 intracranial aneurysms). The mean age was 58.2 years and 35.6% were male. Technical success of the procedure was 100%. RROC1/RROC2 (Raymond-Roy occlusion classification (RROC) 1/2) (total occlusion/neck remnant) at a mean follow-up of 8.9 months was achieved in 94.8%. RROC3 was 4.9%. All-cause mortality was 1.8% and permanent residual neurological deficit or disability was 2.7%. Overall complications at follow-up were 6.2%. Our analysis demonstrated good rates of occlusion at follow-up for aneurysms treated with the Atlas device at follow-up. The safety profile appears similar to other low-profile intracranial stents. |
Databáze: | OpenAIRE |
Externí odkaz: |